Biomarkers Consortium

The Biomarkers Consortium brings together various partners to identify, develop and qualify potential biomarkers to improve drug development and regulatory decision-making. 


Mucosal Healing in Ulcerative Colitis
Mucosal Healing
Biomarkers Consortium Cancer Steering Committee Immuno-Oncology Working Group RFP
IO working group RFP
The ILSA Collaborative Community will highlight partner contributions to the field of liquid biopsy in oncology on a public webinar June 17
FNIH Biomarkers Consortium Launches Project to Select Blood Tests that Detect Early Alzheimer's Disease
Loader and HP - Shutterstock - 2389


The Biomarkers Consortium is a public-private biomedical research partnership managed by the Foundation for the National Institutes of Health (FNIH) that endeavors to discover, develop and seek regulatory approval for biological markers (biomarkers) to support new drug development, preventative medicine and medical diagnostics.


The Biomarkers Consortium is helping create a new era of precision medicine, with more highly predictive markers that have an impact during a patient's illness or lifespan. Its goal is to combine the forces of the public and private sectors to accelerate the development of biomarker-based technologies, medicines and therapies for prevention, early detection, diagnosis and treatment of disease.